|
Jul 23
|
Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
|
|
Jul 22
|
Asian Growth Companies With Strong Insider Ownership In July 2025
|
|
Jul 22
|
High Growth Tech Stocks in Asia for July 2025
|
|
Jul 21
|
Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement
|
|
Jul 14
|
Ascentage Pharma’s Novel Cancer Drug Approved in China
|
|
Jul 14
|
Ascentage Pharma Announces Pricing of Top-Up Placement
|
|
Jul 14
|
Ascentage Pharma Announces Proposed Top-Up Placement
|
|
Jul 10
|
Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug
|
|
Jul 10
|
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
|
|
Jun 15
|
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
|
|
Jun 9
|
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
|
|
May 11
|
Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?
|
|
Oct 8
|
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
|
|
Jun 24
|
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
|
|
Jun 21
|
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
|
|
Jun 18
|
Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR
|
|
Jun 18
|
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL
|
|
May 16
|
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
|
|
Jan 17
|
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)
|
|
Jan 11
|
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
|